MicroBioGen opened new laboratories in Macquarie Park in Northern Sydney to produce micro-organisms for the development of industries worth over USD 2 trillion per year. The new facilities represent a significant investment for the development of an industrial biotechnology hub in Australia.
The new laboratories will allow the expansion of MicroBioGen research capabilities, attract and retain talent helping the company advance in the areas of sustainability, animal feed, and alternative protein. Twice the size of its previous research space, the 1,250 square meter facility will enable MicroBioGen to double its scientific workforce to around forty scientists to continue to develop and advance innovative yeast products. The R&D facility includes fermentation labs, a genetics lab, and large preparation rooms, all equipped with robots, high-performance liquid chromatography, and-80°C freezers.
“It’s great to be here once again at MicroBioGen for the opening of their state-of-the-art laboratory facilities here in the heart of Macquarie Park. They truly are at the forefront of innovation, and their success is part of Australia’s success given that MicroBioGen earns all its revenue through exports. We know that companies such as MicroBioGen are so vital to employment growth locally in Bennelong and through export markets, they are keeping our nation prosperous not just now but also into the future. I’d like to congratulate Geoff Bell, CEO and Dr. Philip Bell, head of research, and all the team here at MicroBioGen on the opening of these wonderful new facilities and I wish them all the very best for the future,” said Jerome Laxale, member for Bennelong.
“We have developed yeast strains that are ideal for human applications such as baking and baking ingredients. Our advanced technology, genetics expertise, and collaborative spirit can also be brought into other industry partnerships to produce cutting-edge enzymes, biochemicals, pharmaceuticals, nutraceuticals, animal feed, and even wine and beer,” said Philip Bell, MicroBioGen’s head of research.
